Skip Navigation

Prostate Cancer Trials

For enrollment information involving the following trials, please contact one of the research staff members listed on Meet the Team.

EDRN FACBC

EDRN Upgrading Study

EDRN PASS

Health Literacy

Sexual Recovery


EDRN FACBC

Validation of FACBC as an Early Indicator of Sub-Clinical Metastatic Disease Among High-Risk Prostate Cancer Patients With Presumed Localized Disease

Inclusion Criteria:

  • High-risk or very-high risk prostate cancer eligible for standard of care surgery

  • At least clinical T3a disease, and/or Gleason >8, and/or PSA>20, as per clinical assessment and routine guidelines

  • Undergone standard of care conventional imaging (CT and/or MR; bone scan and/or NaF PET)

Exclusion Criteria:

  • Definitive findings of systemic metastasis on conventional imaging

Principal Investigator: Mehrdad Alemozaffar, MD

Co-Investigators & Collaborators: David Schuster, MD (Department of Radiology); John Pattaras, MD; Christopher Filson, MD; Kenneth Ogan, MD; Aaron Lay, MD


EDRN Upgrading Study

Biomarkers and Clinical Parameters Associated with Gleason Score Upgrading

Inclusion Criteria:

  • Biopsy-proven Gleason 3+3=6 prostate cancer diagnosed within the past two years

  • Patient scheduled for radical prostatectomy

Exclusion Criteria:

  • Gleason score greater than 3+3=6 on any prior prostate biopsy

  • Any treatment other than radical prostatectomy planned for prostate cancer

  • Prior treatment of the prostate with androgen deprivation, radiation, or other cytotoxic chemotherapy

Principal Investigator: Martin Sanda, MD

Co-Investigator & Collaborator: John Pattaras, MD


EDRN Pass

Canary Prostate Active Surveillance Study Protocol

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of the prostate

  • Clinically localized prostate cancer: T1-2; NX or N0, MX or M0

  • No previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery, or chemotherapy)

  • Prostate biopsy requirements: (A) If diagnosis within one year of baseline visit, participants must have at least one biopsy within at least 10 cores; (B) If diagnosis more than one year prior to baseline visit, participants must have a minimum of two biopsies, one of which must be within two years prior to baseline visit.

Exclusion Criteria:

  • Unwillingness or inability to undergo serial prostate biopsy

  • History of other malignancies, except: Adequately treated non-melanoma skin cancer or adequately treated superficial bladder cancer (Ta) or other solid tumors curatively treated with no evidence of disease for > five years.

Principal Investigator: Christopher Filson, MD

Co-Investigators & Collaborators: Martin Sanda, MD; John Pattaras, MD; Peter Rossi, MD (Department of Radiation Oncology)


Health Literacy

Improving Health Literacy in African-American Prostate Cancer Patients

Inclusion Criteria:

  • Patients who have undergone pathology review of their prostate biopsy with AJCC clinical stage T1-T2 prostate cancer by physical exam

Exclusion Criteria:

  • Unable to undergo the informed consent process and the study interview in English per the judgment of the primary urologist

  • History of head injury or dementia or history of cognitive impairment

Grady/Emory Principal Investigator: Viraj Master, MD, PhD

Co-Investigators & Collaborators: Mehrdad Alemozaffar, MDKenneth Ogan, MD, Martin Sanda, MD;

Atlanta VA Medical Center Principal Investigator: Christopher Filson, MD


Sexual Recovery

True NTH Sexual Recovery Intervention for Prostate Cancer Survivors

Inclusion Criteria:

  • Patients diagnosed with localized prostate cancer who are about to receive definitive treatment with either radiation or prostatectomy without androgen deprivation therapy

  • Patients who also have a spouse/partner who is willing to participate in the study, with both parties required to sign an informed consent

Exclusion Criteria:

  • Anyone unable to speak or read English, unwilling to sign an informed consent form, under the age of 18, or without internet access

Principal Investigator: Akanksha Mehta, MD

««return to top